Tymlos and Zolpidem drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tymlos (abaloparatide) and Zolpidem (zolpidem tartrate). Common drug interactions include fatigue among females and fatigue among males.

The phase IV clinical study analyzes what interactions people have when they take Tymlos and Zolpidem. It is created by eHealthMe based on reports of 85 people who take the same drugs from the FDA, and is updated regularly.

What is Tymlos?

Tymlos has active ingredients of abaloparatide. eHealthMe is studying from 16,516 Tymlos users. Check the latest studies of Tymlos.

What is Zolpidem?

Zolpidem has active ingredients of zolpidem tartrate. It is often used in insomnia. eHealthMe is studying from 92,695 Zolpidem users. Check the latest studies of Zolpidem.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 24, 2026

85 people who take Tymlos and Zolpidem together, and have interactions are studied.

What are the common drug interactions of Tymlos and Zolpidem, by gender? *:

female:

Fatigue (feeling of tiredness)
Headache (pain in head)
Pain
Dizziness
Nausea (feeling of having an urge to vomit)
Heart rate increased
Injection site bruising
Dyspnoea (difficult or laboured respiration)
Pneumonia
Sinusitis (inflammation of sinus)

male:

Fatigue (feeling of tiredness)
Dry mouth
Rash
Sepsis (a severe blood infection that can lead to organ failure and death)
Vomiting
Urticaria (rash of round, red welts on the skin that itch intensely)
Asthenia (weakness)
Flushing (the warm, red condition of human skin)
Headache (pain in head)
Heart rate increased

What are the common drug interactions of Tymlos and Zolpidem, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Mobility decreased (ability to move is reduced)
Nephrolithiasis (calculi in the kidneys)
Osteoporosis (bones weak and more likely to break)
Pain
Pelvic fracture
Ulcer haemorrhage (bleeding ulcer)
Upper limb fracture
Weight decreased
Fanconi syndrome acquired (self developed genetic disease of kidney damage due to defective transport system)
Nephrogenic anaemia (anaemia due to kidney disease)

50-59:

Dizziness
Palpitations (feelings or sensations that your heart is pounding or racing)
Fatigue (feeling of tiredness)
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Decreased appetite
Diarrhoea
Headache (pain in head)
Hypertension (high blood pressure)
Malaise (a feeling of general discomfort or uneasiness)
Nasopharyngitis (inflammation of the nasopharynx)

60+:

Fatigue (feeling of tiredness)
Headache (pain in head)
Dyspnoea (difficult or laboured respiration)
Malaise (a feeling of general discomfort or uneasiness)
Myalgia (muscle pain)
Sepsis (a severe blood infection that can lead to organ failure and death)
Abdominal discomfort
Injection site pain
Injection site reaction
Laziness

What are the existing conditions these people have? *

Osteoporosis Post-Menopausal (weak bone with possibility to break after stopped menstrual cycles): 33 people, 38.82%
Senile Osteoporosis (weak bones with ageing): 24 people, 28.24%
Osteoporosis (bones weak and more likely to break): 19 people, 22.35%
Osteoporotic Fracture (fracture due to weak bone): 5 people, 5.88%
Immunodeficiency Common Variable: 5 people, 5.88%

* Approximation only. Some reports may have incomplete information.

Do you take Tymlos and Zolpidem?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously